Emerging studies suggest Retatrutide , a dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to represent a promising development for weight treatment. Preliminary https://getretatrutideaustralia.com/blog/retatrutide-weight-loss-revolution-2026